ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO017

Urinary Biomarkers as Predictors of AKI in COVID-19 Hospitalized Patients With Pneumonia

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Enriquez, Raul Valeriano, Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico
  • Rizo Topete, Lilia Maria, Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico
Background

COVID-19 disease manifests in most cases as a lower respiratory tract infection. The most frequently reported causes of admission to the intensive care unit in patients with COVID-19 are hypoxemic respiratory failure that requires invasive mechanical ventilation or hypotension that requires support with vasoactive amines. Data on AKI are scarce since they only report on incidence in these patients. The use of microalbuminuria as a marker for AKI was shown in an animal model and correlated with other markers. NGAL has been tested in multiple studies of patients at risk of AKI due to sepsis, cardiac surgery or exposure to contrast media.

Methods

A prospective observational study. Patients who came to the area for COVID-19 were recruited. Upon admission, a urine sample was analyzed with Getein 1100, by quantitative immunofluorescence to determine levels of microalbuminuria and NGAL in 50 patients with creatinine <1.0. All patients had high oxygen requirements (> 5 liters/minute). All patients who had a positive PCR test for SARS CoV-2 were included and patients with a history of chronic kidney disease, urinary symptoms, underlying urological disease or complications of Diabetes or hypertension were excluded. Laboratories were collected at admission and 5 days after admission to compare with initial Ngal and microalbuminuria levels.

Results

The association of the variables was analyzed using the Spearman correlation coefficient, since they are continuous variables. It was found that an elevation of creatinine at day 5 and an initial Ngal> 200 and microalbuminuria >30 have a moderate correlation (rho = 0.46) with a p <0.05, and a low correlation (rho = 0.28) and a p <0.05, respectively.

Conclusion

There is no ideal biomarker for acute kidney injury. With the emergence of COVID-19 disease, it is necessary to be able to prevent and treat acute kidney injury on time, in order to reduce the morbidity and mortality of these patients. In this study, it is observed that 2 biomarkers have a significant correlation to predict acute kidney injury.